ABSTRACT Background: In nonmalaria regions, iron/folic acid supplementation during pregnancy protects newborns against preterm delivery and early neonatal death. Other studies from malaria-endemic areas have reported an adverse effect of iron supplements on malaria prevalence in pregnant women. Objective: We examined the association between iron/folic acid supplements and prenatal antimalaria prophylaxis on neonatal mortality in malaria-endemic countries of sub-Saharan Africa. Design: This analysis used the most recent data from Demographic and Health Surveys of 19 malaria-endemic countries in sub-Saharan Africa. Survival information of 101,636 singleton live-born infants from the most recent delivery of ever-married women 5 y before each survey was examined. The effect of each potential predictor on neonatal deaths was analyzed by using Cox proportional hazards regression models. Results: Infants whose mothers received any iron/folic acid supplements and sulfadoxine-pyrimethamine intermittent preventive treatment (SP-IPT p ) for malaria during pregnancy were significantly protected from neonatal death [hazard ratio (HR): 0.76; 95% CI: 0.58, 0.99]. The protective effect was not significant in mothers who received only iron/folic acid supplements (HR: 0.90; 95% CI: 0.73, 1.12) or only SP-IPT p (HR: 1.08; 95% CI: 0.74, 1.57). Among the sociodemographic and birth characteristics, factors that significantly increased the risk of neonatal death included first-born infants, a birth interval of ,2 y, maternal age at delivery of 30 y, smaller than average-sized infants, and male infants. Conclusion: The use of antenatal iron/folic acid supplements combined with appropriate intermittent preventive treatment of malaria during pregnancy is an important intervention to reduce neonatal mortality in malaria-endemic regions.
INTRODUCTION
Worldwide '4 million infants die every year in the neonatal period (ie, the first 28 d of an infant's life) (1) . Countries with the highest neonatal mortality rates (NMRs) are mostly located in sub-Saharan Africa, where malaria infections because of Plasmodium falciparum also remain an enormous challenge (1) (2) (3) .
Malaria is recognized as a risk factor for maternal anemia (4, 5) , a condition that is prevalent in pregnant women in low-and middle-income countries. Studies have shown an increased of risk of low birth weight and preterm delivery when mothers were anemic during pregnancy (6) . These adverse effects are amplified when women are iron deficient (6) . Intermittent preventive treatment of pregnant women is among the measures recommended to control the effects of malaria in pregnant women and their infants (7) . This entails the administration of antimalaria prophylaxis for pregnant women, irrespective of the presence of parasites or symptoms (7) . Sulfadoxine-pyrimethamine intermittent preventive treatment (SP-IPT p ) is recommended as an effective antimalaria prophylaxis in sub-Saharan Africa, where the transmission of P. falciparum is stable (8) . Two doses of SP-IPT p at the first and second scheduled antenatal check after movements of the fetus are noted provide the greatest protection (9) .
To prevent iron-deficiency anemia during pregnancy, the provision of iron/folic acid supplements is also recommended (10) . A number of trials have examined the benefits of iron/folic acid supplements in pregnancy; however, they have mainly focused on maternal outcomes, such as maternal hemoglobin status rather than neonatal outcomes (11) . A recent trial from China reported that the risk of early neonatal deaths was reduced by 54% in women who took iron/folic acid compared with those taking folic acid alone (12) . These results are supported by findings from the United States in nonanemic pregnant women that show a lower incidence of low birth weight and preterm deliveries in women taking iron supplements (13, 14) . Our previous analysis used national surveillance data from Indonesia and showed a 47% reduction of the risk of early neonatal deaths in mothers who reported taking any iron/folic acid supplements during pregnancy (15) .
Regardless of the beneficial effect of iron/folic acid supplements, there have been reports of an adverse effect of iron supplements on malaria infections in children (16) and pregnant women living in malaria-endemic areas (17) . In these studies, the rate of malaria infections was reported to increase in women and children who received iron (16) (17) (18) (19) . However, a recent metaanalysis showed no evidence of adverse effects of iron treatment in children from endemic-malaria areas (20) . A randomized controlled trial from a malaria-endemic region in The Gambia conducted in multigravid pregnant women also reported no evidence of an increased susceptibility to malaria infection in women who received 60 mg elemental iron compared with women in the placebo group (21) .
This conflicting evidence highlights the importance of examining the role of iron/folic acid supplementation in pregnant women to implement evidence-based antenatal care (ANC) that benefits both mothers and children in malaria-endemic regions. This study aimed to examine the hypothesis that infants in malaria-endemic areas whose mothers received ANC services of iron/folic acid supplements and antimalaria prophylaxis would have a reduced risk of neonatal deaths.
SUBJECTS AND METHODS

Data sources
Our analyses used the most recent data from Demographic and Health Surveys (DHS) of 19 malaria-endemic countries in subSaharan Africa. DHS are nationally representative surveys conducted in around 70 countries since 1984 that aim to collect information about demographic and population health status including fertility, family planning, maternal and child health, and childhood mortality (22, 23) . Women of reproductive ages are the main focus of these surveys. Details about the neonatal deaths were derived from the Women's Questionnaire, which collected a chronologic list of all the woman's live births, the date of the birth, as well as the child's survival status on the day of interview. More details of the sampling methods used in the DHS have been described elsewhere (24) .
The selection of countries used in this study was based on the following 3 criteria: 1) the malaria endemic rate was 80% of the population (8) [an exception was Zimbabwe, which has been commonly accepted as a malaria-endemic country (23) and was included in these analyses although its endemic rate was not available in reference 8], 2) DHS data were available from 2003 onwards, and 3) information concerning sociodemographic and birth characteristics and pregnancy or delivery service factors was reported in the DHS dataset. The 19 countries selected, which were ordered by their rate of neonatal mortality from the lowest to the highest, were Zimbabwe Table 1) .
Survival information of 101,636 singleton live-born infants from the most recent delivery of ever-married women within 5 y before each survey was examined in this analysis. These births were selected in our study because the majority of health-service information collected in the DHS was only available for these births. This restriction reduced the recall bias that might have arisen if women recalled the details about their pregnancies and childbirths from various time periods after birth. Outcome and exposure factors
The outcome of this study was neonatal death, which was defined as the death of a live-born singleton infant during the first 30 d of life, from the most recent delivery of ever-married women 5 y before each survey. This information was obtained from the birth histories of the mothers interviewed in each survey.
The exposure variables were iron/folic acid supplements and antimalaria prophylaxis. A standard DHS Women's Questionnaire was used to ask mothers whether they were given or bought any iron tablets or iron syrups during pregnancy. Further questions about the number of days the mothers took the tablets or syrups were asked if the mothers reported that they were given or had bought iron supplements. Mothers were also asked if they took any drugs to prevent malaria during pregnancy and the name of the drugs taken. A composite variable of the use of iron/folic acid supplements and use of antimalaria prophylaxis was constructed to assess the effect of different combinations of these interventions on neonatal deaths.
An adaptation of the Mosley and Chen framework for the study of child survival in developing countries (25) was applied in our study to examine the relation of sociodemographic and birth characteristics and delivery care services received by mothers with neonatal death. All of these variables were categorized into the following 2 main groups of variables: 1) sociodemographic and birth characteristics and 2) antenatal and delivery care services.
To represent the sociodemographic and birth characteristics, 13 factors were examined as follows: country, type of place of residence, highest maternal educational attainment, highest paternal educational attainment, maternal marital status, maternal religion, parental occupation, household-wealth index, child sex, maternal desire for pregnancy, maternal age at childbirth, combined birth rank and birth interval, and birth size ( Table 2) . Maternal subjective assessment of the size of the infants at birth was used to replace the birth-weight variable because of a large proportion of infants who were not weighed at birth (57%). The three categories of birth size used in these analyses were smaller than average, average, and larger than average, with a mean of birth weight of 2490, 3056, and 3595 g, respectively. A new household wealth-index variable was constructed from pooled DHS data for all 19 countries by assigning weights to 7 housing characteristics and household assets (ie, availability of electricity and possession of a radio, television, refrigerator, bicycle, motorcycle, and car) by using a principal components analysis method (26) . In addition to the main study factors, the other pregnancy, delivery, and postdelivery care-service variables examined in this study were place of delivery, mode of delivery, delivery attendance, ANC services, tetanus toxoid (TT) vaccination, and breastfeeding. ANC in this study referred to any use of health care services during pregnancy by trained attendants (doctors, nurses, and midwives). All of the information used in this study was selfreported.
Statistics
A frequency tabulation was performed to describe the characteristics of the population used in these analyses. Bivariate analyses using Cox proportional hazards regression analysis were conducted to measure the crude hazard ratio (HR) of each possible predictor, which were followed by multivariate analyses to investigate the independent effect of these variables after adjusting for other covariates.
In the first stage of multivariate analyses, all potential predictors of sociodemographic and birth characteristics were entered simultaneously, and a backward elimination procedure was applied to remove factors from the model that were not statistically significant at the 5% level. Three variables, the country indicator, the age of the child (in days), and household-wealth index, which were previously shown to be associated with an increased risk of neonatal mortality (27, 28) , were selected a priori and retained in the model regardless of their level of significance. In the second stage, the effect of antenatal and delivery care services (ie, ANC, mode of delivery, place of delivery, and delivery attendance) were assessed and adjusted for significant variables of sociodemographic and birth characteristics. Only the significant predictors were retained in the model. Because ANC was shown to be highly correlated with TT, iron/folic acid supplementation, and antimalaria prophylaxis, these components replaced ANC and were entered one at a time into the final model. A composite variable of iron/folic acid supplements and antimalaria prophylaxis was then entered to assess the effect of different combinations of these services on neonatal deaths.
The population attributable risk (PAR) (29, 30) was calculated to measure the total risk of neonatal deaths in the population that was attributable to women who did not take both iron/folic acid supplements and SP-IPT p . To calculate the PAR, the HR of the risk factors (aHR) compared with the remainder of the population was calculated by using Cox proportional hazards regression analysis and adjusted for factors included in the final model. Secondly, the population exposed (Pe) to the risk factors was calculated by using a weighting factor that took into account both the within-survey weights and a weight for the variation of the population size of each of the 19 countries included in the study. The PAR was calculated by using the following equation:
In the analyses presented, we used Cox proportional hazards models that were adjusted to take account of the sampling weights and the cluster-sampling design. Survey commands were used in the analyses to adjust for the effects of the cluster-sample survey designs. The HR and 95% CI were calculated for factors associated with neonatal deaths. All statistical testing was performed with STATA/MP version 10.00 (2007; Stata Corporation, College Station, TX) by using the survey commands, and all results were weighted by the sampling probabilities used in each survey.
RESULTS
Information on 2001 neonatal deaths was obtained for our analyses and ranged from 57 cases in Zimbabwe (NMR 5 y preceding the survey = 124/1000) to 219 neonatal deaths in Mali (NMR: 46/1000) ( Table 1) (23) .
A total of 185,383 eligible women were interviewed in the DHS of the 19 countries, and the neonatal survival information from 100,683 singleton live-born infants of the most recent births of the mothers 5 y preceding each survey was used in the analyses. The characteristics of antenatal and delivery care services for all 19 countries combined are shown in Table 2 . More than 77% of infants were born to mothers who received ANC services, and 66% of mothers received iron/folic acid supplements, but only 20% of mothers received SP-IPT p as antimalaria prophylaxis. Less than 16% of mothers received both iron/folic acid supplements and SP-IPT p .
The sociodemographic and birth characteristics of the women, as well as the association of these characteristics with neonatal mortality, are shown in Table 3 . Approximately 72% of women were from rural areas and 51% of the mothers did not have a formal education. An increased risk of neonatal deaths was observed in first-born infants, infants with a birth interval of ,2 y, infants whose size at birth, according to the perceptions of the mothers, was smaller or larger than average, and male infants. When the birth-size variable was replaced by infant weight at birth, the risk of neonatal deaths increased by 1.7 times (HR: 2.66; 95% CI: 2.01, 3.52; P , 0.001) in infants who weighed ,2500 g and by almost one-half (HR: 1.43; 95% CI: 1.10, 1.85; P = 0.01) for infants who weighed .3500 g compared with infants who weighed 2500-3500 g at birth. Infants born to mothers aged 30 y also showed an increased risk. Approximately 87% (95% CI: 86.6, 87.8) of infants born to mothers aged 30-39 y were the fourth or higher births for those women, which was also the case for 97% (95% CI: 96.5, 97.5) of infants born to mothers aged 40 y.
Among pregnancy and delivery care factors, the risk of neonatal deaths was reduced in mothers who received ANC services (Figure 1) . When ANC was replaced by TT vaccinations, iron/folic acid supplements, and antimalaria prophylaxis one at a time, the HR decreased significantly if the mothers took any iron/folic acid supplements and decreased with borderline significance for use of antimalaria prophylaxis After antenatal, delivery, and postdelivery care services and delivery attendants were controlled for, the analysis, which used a combined variable of iron/folic acid supplements and antimalaria prophylaxis, showed that the risk of neonatal deaths was significantly reduced by 24% for infants whose mothers took both iron/folic acid supplements and SP-IPT p (HR: 0.76; 95% CI: 0.58, 0.99) (Figure 2) . In mothers who reported taking any antimalaria prophylaxis and any iron/folic acid supplements during pregnancy, we observed a dose-response effect of iron/ folic acid supplements as the HR reduced by 18% (HR: 0.82; 95% CI: 0.69, 0.99) in mothers who reported taking ,90 tablets of iron/folic acid supplements and by 24% (HR: 0.76; 95% CI: 0.61, 0.95) in mothers who reported taking 90 tablets. After the combined effect of iron/folic acid supplements and antimalaria prophylaxis was controlled for, 2 TT vaccinations did not significantly reduce the risk of neonatal deaths. 
FIGURE 1.
Comparison of the effects of antenatal care (ANC) service, iron/folic acid supplements (FeFol), malaria prophylaxis, and tetanus toxoid vaccinations (TT) on neonatal mortality (obtained by using Cox proportional hazards regression analysis). These models are separate models that were adjusted for sociodemographic and birth characteristics reported in Table 2 (ie, country, maternal marital status, household-wealth index, sex of child, desire for pregnancy, maternal age at childbirth, combined birth rank and interval, size at birth, age of child in days, breastfeeding, mode of delivery, and delivery attendance). All values are weighted for sampling probability. (See supplemental Tables 1-4 under "Supplemental data" in the online issue for details of these models; also see supplemental Table 5 under "Supplemental data" in the online issue for the results of the univariate analysis of the pregnancy and delivery health care service factors.) ref, reference; SP-IPT p , sulfadoxine-pyrimethamine intermittent preventive treatment.
Assuming a causal association between neonatal death and not taking the combination of iron/folic acid supplements and SP-IPT p , the PAR calculation showed that, in all 19 countries included in this study, the proportion of neonatal deaths attributed to a lack of both iron/folic acid supplementation and SP-IPT p was 18% (PAR: 0.18; 95% CI: 20.01, 0.33). This PAR was calculated by using the HR of 1.24 (95% CI: 0.99, 1.55), which was the risk of neonatal deaths in women who did not take the combination of iron/folic acid supplements and SP-IPT p , compared with women who took both iron and SP-IPT p . The PAR also varied from 8% in Zambia to 19% in Niger. By using the HR for women who did not take either iron/folic acid supplements or SP-IPT p compared with women taking both iron/folic acid supplements and SP-IPT p (HR: 1.32; 95% CI: 1.01, 1.72), we calculated that 24% of neonatal deaths could be averted by the combination of iron/folic acid supplements and SP-IPT p in settings where ANC services are lacking (assuming coverage of only 1%).
DISCUSSION
Main findings and their significance
Our analyses revealed that infants from malaria-endemic countries were significantly protected from neonatal death when their mothers received iron/folic acid supplements, even after we adjusted for use of ANC services by the mother. The benefit of taking iron/folic acid supplements was maximized when they were taken with antimalaria prophylaxis, in particular SP-IPT p . In women who took any antimalaria prophylaxis, we also observed a dose-response relation of a greater reduction of HR for neonatal mortality in women who reported taking a higher number of iron/folic acid supplements. The results of this study show that iron/folic acid supplements play an important role in preventing neonatal deaths in nonmalaria-endemic countries (12, 15) and in the malaria-endemic countries of sub-Saharan Africa. Therefore, the provision of iron/folic acid supplements along with effective antimalaria prophylaxis should be included among the essential ANC services in neonatal care packages to prevent neonatal deaths in malaria-endemic regions.
Biological mechanisms
The protective effect of iron supplements on neonatal deaths has been shown in different studies in developing countries (12, 15) . These neonatal mortality-sparing effects are likely mediated through the prevention of preterm low birth weight, one of the main contributors to neonatal deaths in developing countries (31) . Several pathways have been postulated through which iron/folic acid supplements might affect gestation and birth weight, including the transfer of iron to the placenta and fetus that leads to a higher birth weight (13) , and the prevention of changes in hormonal factors such as corticotrophin-releasing hormones that might adversely affect gestation and fetal growth (32) . Another study showed the protective effect of iron on birth asphyxia (12) , which is known as one of the main contributors for neonatal death worldwide (1) .
The effects of iron in preventing preterm delivery may have been reduced by the presence of inflammation in the pregnant women. A study that involved apparently healthy HIV-positive Kenyan adults showed that the synthesis of hemoglobin as a result of iron supplementation only occurred normally when inflammation was not present (33) . When inflammation was present, erythropoiesis was inhibited, and iron supplementation only led to an increased plasma ferritin concentration (33) . These findings suggest that inflammation from malaria infections during pregnancy might hinder the intake of iron and lead to higher rates of preterm delivery. This would explain the findings from our study that showed that the benefit of iron/folic acid supplements in preventing neonatal death was maximized when women took both iron/folic acid supplements and antimalaria prophylaxis during pregnancy. Our findings of a protective effect of iron/folic acid supplements are consistent with the results from other studies, including a trial from China (12) , the results of the Jamaican Mortality Survey (34) , and similar analyses that used FIGURE 2. Combined effect of iron/folic acid supplements (FeFol) and malaria prophylaxis on neonatal mortality (obtained by using Cox proportional hazards regression analysis). This model was adjusted for sociodemographic and birth characteristics as reported in Table 2 (ie, country, maternal marital status, household-wealth index, sex of child, desire for pregnancy, maternal age at childbirth, combined birth rank and interval, size at birth, age of child in days, breastfeeding, mode of delivery, delivery attendance, antenatal care services, and tetanus toxoid vaccination). All values are weighted for sampling probability. (See supplemental Table 6 under "Supplemental data" in the online issue for details of this model; also, see supplemental Table 5 pooled DHS data from Indonesian where malaria transmission is low (15) . Compared with these earlier studies, the strength of the protective effect of iron/folic acid supplements in pregnancy for neonatal mortality was lower in the current study. This may have been due to possible residual inflammation of HIV/AIDS in populations of women of reproductive age from the sub-Saharan African region or differences in the timing in the start of ANC and the use of iron/folic acid supplements.
Comparisons with previous studies
Our findings allow a reinterpretation of an earlier trial from Kenya conducted in primigravid women in which a 38% (95% CI: 28%, 65%) reduction of neonatal deaths was observed in mothers who received SP-IPT p compared with those in the placebo group with no prophylaxis for malaria (35) . This trial has been interpreted to provide evidence of the protective effective on neonatal deaths of intermittent preventive treatment of malaria in pregnancy; however, the pregnant women in both treatment groups received a 30-d supply of ferrous sulfate tablets, which indicated that the combination of iron/folic acid supplements and SP-IPT p was protective for early neonatal mortality compared with the effect intermittent preventive treatment alone. To our knowledge, there has been no trial that has compared the effects of these 2 interventions alone or looked for an interaction of their effects on neonatal mortality. It is widely recognized that controlled trials of iron/folic acid supplementation in pregnant women are considered practically impossible for ethical reasons (36) . The combinations of our findings and the earlier results from Kenya suggest the need for trials to examine the use of iron/folic acid supplements during pregnancy with and without SP-IPT p . However, with the currently available studies, our findings provide important evidence to guide policy decisions about these interventions and to highlight the importance of combining iron/folic acid and effective antimalaria prophylaxis to prevent neonatal deaths in populations at risk of malaria. The benefits and safety of iron supplements for pregnant women in malaria-endemic areas has been raised (37) because a recent study from Tanzania showed a decreased susceptibility to P. falciparum infection in pregnant women who were iron-deficient (19) . These results suggested that iron supplementation in pregnancy might increase the risk of maternal malaria. The study used the concentration of C-reactive protein (CRP) as an indicator of inflammation and an adjusted ferritin cutoff to define iron deficiency if inflammation was present. When inflammation was absent, the standard ferritin concentration of ,30 ng/mL was used, but when inflammation was present, this cutoff value was raised to a ferritin concentration of ,70 ng/mL. With the use of these criteria, a reduced prevalence of placental malaria at delivery was shown when women were iron deficient. However, the ferritin concentration varies across the stages of inflammation (incubation, sickness, and convalescence), and an accurate assessment of the stage of inflammation is important to measure the appropriate cutoff point of the ferritin concentration (38, 39) . Measures of plasma concentrations of 2 acute-phase proteins, CRP, and a-acid glycoprotein are required to accurately measure the stage of inflammation, but relying only on the CRP concentration to set the cutoff point to define low ferritin concentrations, as was done in the study from Tanzania, might have lead to biased results (38, 39) .
The use of folic acid supplements for women in malaria endemic areas has also been raised as a concern because there have been reports of a reduction in the efficacy of sulfadoxinepyrimethamine (SP) that is attributable to its coadministration with folic acid (40, 41) . Because the antiparasitic activity of SP is mediated by interfering with the folic acid metabolism of parasites, a high folate concentration is assumed to benefit P. falciparum growth. Although the results of a trial from the Gambia with primigravid women revealed that, in areas of low SP resistance, the coadministration of SP and folic acid to pregnant women did not compromise the protective effect of SP (42) ; the suggestion of withholding folic acid supplementation for a minimum period of 1 wk after antifolate drug administration should be taken into consideration (41) .
Strengths and limitations
A key strength of this study was the data source of pooled national survey data from 19 malaria-endemic countries of subSaharan Africa, which provided a sample size with sufficient power to examine neonatal mortality rates in subgroups of interest. The same core questionnaires were also used in all DHS, which were conducted with consistent survey quality-control methods. The restriction of the study population to the most recent births of mothers, 5 y before each survey, minimized the possibility of the recall bias of the mothers and, therefore, increased the validity of our study (43, 44) . Our analyses also took into account a variety of sociodemographic and birth characteristics that might potentially confound the relation between our main study factor and the outcome. This adjustment also led to an improvement of the validity of the analyses of the primary study factor.
Several limitations of this analysis should also be considered when evaluating the results. The selection of the covariables for the survival models was mainly driven by the availability of the information across the surveys datasets. The presence of HIV infection in pregnant women, which was not available in the DHS data, might have affected the relation between the use of iron/folic acid supplements and the risk of neonatal mortality because inflammation in the HIV-positive women might have reduced the response to iron. Because data used in this analysis were taken from DHS, reporting the use of iron/folic acid supplements and antimalaria prophylaxis might be subject to recall bias and measurement error because this information was self-reported and relied on the mothers' recollection about their use of iron/folic acid supplements and antimalaria prophylaxis. This might have biased the results by potentially underestimating the effects of iron/folic acid and malaria prophylaxis on the risk of neonatal death. Finally, our analyses did not differentiate primigravid women, who are more vulnerable to malaria, from multigravid women because of sample-size restrictions. Overall, these limitations are unlikely to have influenced the validity of our results.
In conclusion, our analyses showed that infants were significantly protected from neonatal deaths when mothers took both iron/folic acid and antimalaria prophylaxis. The provision of both iron/folic acid supplements and effective antimalaria prophylaxis should be included in ANC services to reduce neonatal deaths in malaria-endemic countries. Health care professionals should be encouraged to promote the use of iron/folic acid supplements and effective antimalaria prophylaxis in women who live in malariaendemic areas and especially where health care services are limited.
